Society for Laboratory Automation and Screening 2018

Society for Laboratory Automation and Screening 2018

3 Feb 2018

SLAS 2018

Join us at SLAS 2018, Sartorius booth #1419

Visit Essen BioScience, now a Sartorius company, at Sartorius booth #1419 and attend our power packed scientific program to learn more about our innovative IncuCyte® S3 Live-Cell Analysis System. Whether simply assaying cell health or more complex processes like migration, invasion, or immune cell killing, find out how the IncuCyte® Live-Cell Analysis System, and IncuCyte® reagents let you see what happened and when—without ever removing your cells from the incubator.

Learn more about SLAS 2018

IncuCyte® Live-Cell Analysis System

  • Combine the power of imaging with the dimension of time
  • Multiparametric measurements in multi-well format
  • Streamlined workflow with automated analysis

Product Launches / Technology Developments

  • Automated live-cell assays using spheroid models
  • New Antibody Internalization solution suitable for profiling antibody panels 


Automated measurements of immune cell killing of 3D tumor spheroids using live-cell analysis

Presenter: Aaron Overland or Cicely Schramm
Poster Board Number: 1171-B
Presentation date/time: Monday, February 5 — 5:00-6:00 PM  
Authors: Dan Appledorn*, Minnie Oliver, Kalpana Patel*, Nevine Holtz*, Eric Endsley*, Cicely Schramm*, Aaron Overland*, Tim Dale and Del Trezise. Essen BioScience R&D, Welwyn Garden City, Hertfordshire UK and *Ann Arbor, Michigan USA.

Immunotherapies such as checkpoint inhibitors, CAR-Ts and immune-targeting Abs have great promise for cancer treatment. Tumor spheroid models offer more translational biological insight than 2D cell models and provide a more physiologically relevant model for testing immunotherapy biologics in vitro. In this study, we describe a novel, medium throughput immune cell-killing assay using automated live-cell analysis of 3D tumor spheroids.

Kinetic antibody internalization assays for drug discovery using live-cell analysis

Presenter: Aaron Overland or Cicely Schramm 
Poster Board Number: 1179-E
Presentation date/time:
Wednesday, February 7 — 11:30 AM - 12:30 PM 
Authors: Dan Appledorn*, Nicola Bevan*, Aaron Overland*, Cicely Schramm*, Tim Dale and Del Triese. Essen BioScience R&D, Welwyn Garden City, Hertfordshire UK and *Ann Arbor, Michigan USA.

Monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs) are widely used biological therapeutics.   A key property of these biologics is the extent and rate of internalization into different cells, which governs their efficacy, safety and pharmaco-dynamic profile. As a result, quantifying and comparing the rate of Ab internalization of drug candidates and production batches is a critical step in the biopharmaceutical selection and optimization process. 

Connect & Discover

Connected for the first time under the Sartorius umbrella are four innovative live-cell platforms supporting drug discovery and bioanalytic applications –  iQue Screen PLUS, IncuCyte®, CompacT SelecT™ and ambr15®.

From the provision of high quality adherent cells in assay-ready plates or multi-parallel suspension cell cultures, to long-term real-time live-cell imaging or high speed suspension cell and bead-based assays, these flexible walk-away automation solutions from Sartorius provide the superior cells, data and analytical capability that deliver deep insights and increase your productivity.

Attend the scientific program or stop by at Sartorius booth 1419 to learn more about these platforms.

IntelliCyt Suspension Cell & Bead Analysis System

  • Rapid, microvolume sampling combined with real time analysis
  • Screen antibodies & compounds, cells & beads together
  • Profile phenotype & function, immune cell monitoring

Exhibitor Tutorial

Advances in Antibody Discovery and Adoptive Cell Therapy Enabled by Novel Applications using High Throughput Multiplexed Suspension Cell Screening

Therapeutic antibodies continue to be clinical success stories, especially in the area of immuno-oncology. Recent times have also seen dramatic progress being made in the area of adoptive T-cell therapies.  Therefore, providing efficiency gains in the antibody discovery and cell therapy development processes has become a focus of effort at IntelliCyt, a Sartorius Company.  Several new application kits have been developed that combine process steps through multiplexing and run on our platform, providing productivity gains in both sampling throughput and analysis/visualization workflows. Several customer case studies will be discussed.

Date: February 6th 2:00 p.m. - 2:45 p.m.
Room: 11a

SLAS Speaker Ashok BandaranayakeAshok Bandaranayake
Director of Bioprocess Development and Automation, Fred Hutch Cancer Center

Topic: Incorporation of the iQue Screener PLUS into a novel protein production and drug discovery platform

SLAS Speaker Alison TarkeAlison Tarke
Research Scientist, PersImmune

Topic: Screening of AML Neoantigen Specific T cells with the iQue Screener PLUS


Acceleration of Antibody Development Campaigns from Cell Line Generation through Functional Characterization Using the iQue® Screener Platform

Poster ID:
Presentation date/time: Wednesday, February 7 — 11:30 AM - 12:30 PM

Generating antibodies specific to membrane-spanning proteins in their native conformation is very challenging, yet crucial for therapeutic and diagnostic antibody development. The advantage of traditional cell-based assays is that they facilitate the study of antibody-antigen interactions in their native environment, however, they are limited by low sample throughput and require large sample volumes. The iQue Screener platform increases the throughput of suspension cell-based assays to several thousand samples/day using minimal sample volumes. This enables the screening of large antibody panels for properties beyond mere antigen binding to support a campaign from the cell line generation process through functional characterization. In this study, we highlight the experience of ModiQuest Research and how they have implemented the use of the iQue Screener across the antibody development workflow. In addition, ForeCyt® Software removes the data analysis bottleneck with its advanced data visualization capabilities and plate-level analytics that enable rapid identification of positive hits. With the iQue Screener platform, ModiQuest Research has developed increasingly complex, multi-criteria eir sample volume requirements, time to results and FTE requirements while maximizing their chances of finding therapeutic leads in less time.

Presenter: Zhaoping Liu
Poster Board Number: TBA
Authors: Tom Duensing, IntelliCyt Corp. and Andrea Gorlani, Ph.D., ModiQuest Research

IntelliCyt Cy-Clone Type-n-Titer (Mouse) Assay and ForeCyt Analytic Algorithms Streamlines Antibody Discovery

Zhaoping Liu 
Poster Board Number: TBA
Authors: Zhaoping Liu and John O’Rourke , IntelliCyt Corp

Monoclonal antibodies are the fastest-growing class of therapeutic agents with success in treating a wide range of diseases such as cancer, cardiovascular disease, autoimmune disorders and infectious disease. Most therapeutic antibody candidates are initially generated from mouse hybridomas or primary B cell clones after antigen immunization. In the antibody discovery workflow, primary screens identify clones with specific attributes (i.e. binding specificity, cross species reactivity, selectivity and affinity). Potential candidates from the screen are assessed for a variety of critical parameters such as IgG isotyping, antibody quantification, and cell number/health which is vital information for lead molecule generation.

Quantification of mouse antibody from cell culture supernatant is traditionally assessed using enzyme-linked immunosorbent assay (ELISA).  ELISA is a time consuming, single-endpoint assay, often requiring sample dilution and multiple washes. Additionally, separate IgG isotyping and cell count/health assays are performed to provide the scientific insight for downstream antibody cloning. IntelliCyt disrupts this traditional workflow with a novel solution: Cy-Clone Type-n-Titer (Mouse) assay, a patented high throughput, multiplexed assay coupled with IntelliCyt’s ForeCyt data analysis software. This platform streamlines antibody discovery, identifying optimal clones for downstream processes.

CompacT SelecT adherent cell culture automation

  • Optimal maintenance, expansion and plating of cell lines
  • Improved culture of delicate or complex cell lines
  • Increases throughput elimination of process contamination

Product Launches / Technology Developments

  • Integration of IncuCyte S3 Live-Cell Analysis System into CompacT SelecT
  • CompacT SelecT Data API

ambr15 advanced microscale bioreactor system

  • Multi-parallel suspension cell culture for cell line selection
  • Create better cell lines faster and cheaper
  • Predictive of larger scale stirred tank bioreactor performance

Learn more about SLAS 2018

No file selected
Stay up-to-date with what's happening at Essen BioScience

© 2023 Essen BioScience

Privacy Policy